History Can Teach Us Something: Angiogenesis Inhibition Revisited.

Competing Interests: Disclosure Dr. Eberhardt has a clinical research grant for an Investigator Initiated Trial by AstraZeneca given to his institution; received consulting fees for advisory boards by AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Eli Lilly, Roche, Boehringer Ingelheim, Amgen, Takeda, Pfizer, Sanofi, Regeneron, and Onkowissen; has personally received honoraria for educational lectures by AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Eli Lilly, Roche, Boehringer Ingelheim, Amgen, Takeda, Sanofi, Regeneron, and Pfizer. Dr. Sebastian has a clinical research grant for an Investigator Initiated Trial by AstraZeneca given to his institution; received consulting fees for advisory boards by AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Eli Lilly, Roche, Boehringer Ingelheim, Amgen, Takeda, Pfizer, Sanofi, Merck, GSK, and Onkowissen; has personally received honoraria for educational lectures by AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Eli Lilly, Roche, Boehringer Ingelheim, Amgen, Takeda, Merck, GSK, Daiichi-Sankyo and Pfizer.